Pacira BioSciences Reports Q2 2025 Revenue Growth but Net Loss

Pacira BioSciences, Inc. reported its financial results for the second quarter of 2025, revealing total revenues of $181.1 million, a 2% increase from $178.0 million in the same period last year. The growth was primarily driven by a 4% rise in net product sales of EXPAREL, which reached $142.9 million, and a 2% increase in ZILRETTA sales, totaling $31.3 million. However, the company experienced a significant decline in royalty revenue, which fell by 54% to $752,000, attributed to timing issues related to orders for veterinary use. For the first half of 2025, total revenues were $350.0 million, up slightly from $345.1 million in the prior year.

Despite the revenue growth, Pacira reported a net loss of $4.8 million for the second quarter, compared to a net income of $18.9 million in Q2 2024. The loss was influenced by increased operating expenses, which rose to $172.6 million from $149.8 million a year earlier. This increase was driven by higher selling, general, and administrative costs, which surged by 30% to $88.6 million, reflecting investments in marketing and sales initiatives. Research and development expenses also rose significantly, increasing by 39% to $28.2 million, as the company advanced its clinical trials and product development efforts.

In terms of strategic developments, Pacira completed the acquisition of GQ Bio Therapeutics GmbH in February 2025, enhancing its capabilities in gene therapy with the HCAd platform. The company also announced a collaboration with Johnson & Johnson MedTech to co-promote ZILRETTA, aiming to expand its market reach. Additionally, Pacira decommissioned its 45-liter EXPAREL batch manufacturing suite in San Diego, resulting in a workforce reduction of approximately 8%, which is expected to yield annual savings of about $13 million.

Operationally, Pacira's cash and cash equivalents increased to $300.5 million as of June 30, 2025, up from $276.8 million at the end of 2024. The company also reported a total asset value of $1.54 billion, with total liabilities of $779.5 million. The company’s employee headcount was reduced to approximately 800 following the recent restructuring. Looking ahead, Pacira anticipates continued investment in its product pipeline and expects to leverage its recent acquisitions to drive future growth, despite the challenges posed by market conditions and increased competition.